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Abstract
Background
Measles outbreaks have occurred in some countries despite supplementary immunization
activities (SIA) using measles-containing vaccine with high vaccination coverage. We con-
ducted a cross-sectional seroprevalence survey to estimate population immunity in Lao
People’s Democratic Republic where repeated mass immunization has failed to eliminate
measles.
Methods and findings
In this nationwide multistage cluster sampling survey conducted in 2014 based on probabil-
ity proportionate to size sampling, blood samples were collected from 2,135 children and
adults living in 52 randomly selected villages. Anti-measles and anti-rubella IgG were mea-
sured, and IgG prevalence was calculated. We applied mathematical modelling to estimate
the number of cases of congenital rubella syndrome (CRS) in 2013 that were averted by the
2011 SIA. A stability testing was applied to the MR vaccine at 4˚C, 25˚C, and 35˚C to exam-
ine stability differences between measles and rubella vaccine components. Measles IgG
prevalence was significantly lower in the target age groups (5–21 years) of the 2011 SIA
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using a combination vaccine for measles and rubella vaccine (MR vaccine) than in young
adults (22–39 years) (86.8% [95% CI: 83.0–90.6] vs. 99.0% [98.3–99.8]; p<0.001), whereas
rubella IgG prevalence was significantly higher (88.2% [84.5–91.8] vs. 74.6% [70.7–78.5];
p<0.001). In the SIA target age groups, prevalence of measles IgG, but not rubella IgG,
increased with age. CRS cases prevented in 2013 ranged from 16 [0–50] to 92 [32–180] if
the force of infection had remained unchanged or had been reduced by 75%, respectively.
In freeze-dried conditions, the measles vaccine component was more heat sensitive than
the rubella component.
Conclusions
Inconsistent IgG prevalence between measles and rubella in Lao PDR can be partly
explained by different stability of the measles and rubella vaccine components under heat
exposure. Suboptimal vaccine handling may cause insufficient immunogenicity for measles,
which subsequently leads to an outbreak despite high SIA coverage, while direct evidence
is lacking. Temperature monitoring of the vaccine should be conducted.
Introduction
Measles and rubella are vaccine-preventable viral diseases that remain important causes of
death and disability, especially in countries with limited health systems. Measles killed 2.6 mil-
lion people globally every year before the measles vaccine came into widespread use, and still
killed 145,700 infants before their first birthday in 2013 despite 83–84% measles immunization
coverage for the infant population worldwide [1–3]. Rubella is a mild self-limited illness occur-
ring mainly in children, but infection before conception or during early pregnancy may cause
miscarriage, foetal death, or severe congenital defects known as congenital rubella syndrome
(CRS) [4]. More than 100,000 babies are estimated to be born with CRS worldwide annually
[4, 5, 6, 7].
Lao People’s Democratic Republic (PDR) is a landlocked developing country with poor
infrastructure, with 10% to 13% of vaccine procurement funded under the national budget.
Measles is one of the country’s priority vaccine-preventable diseases and an expanded pro-
gramme on immunization (EPI) started in 1984. Under this EPI, measles-containing vaccina-
tion coverage among 12 month olds increased from 6% to 42% between 1984 and 2000
[Ministry of Health]. After several outbreaks occurred, nationwide SIA were implemented in
2001 (86% coverage), 2007 (96% coverage), and 2011 (97% coverage) using measles-containing
vaccines. A monovalent vaccine was used both for the 2001 SIA, targeting children aged 9
months to 4 years, and the 2007 SIA, targeting children aged 9 months to 14 years, and the
combination vaccine for measles and rubella (MR vaccine) was introduced for the 2011 SIA
targeting children aged 9 months to 19 years. Despite these efforts, the country continued to
experience measles outbreaks. For example, even as measles immunization coverage increased
from 50% to 82% from 2001 to 2013 and SIA coverage was 96% and 97% in 2007 and 2011,
respectively, measles outbreaks occurred in 2012, 2013, and 2014 [Ministry of Health]. The
exact causes of the measles outbreaks are unknown and need to be investigated to prevent fur-
ther outbreaks.
To this end, we conducted a nationwide multistage random cluster sampling survey in 2014
to measure anti-measles and anti-rubella IgG prevalence among children and adults in Lao
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PDR with the aims of estimating population immunity, evaluating previous vaccination effec-
tiveness, and then estimating through mathematical modelling the number of CRS cases
averted by the 2011 SIA. We also conducted a stability test to evaluate the stability of measles
and rubella vaccine components, since the information may be useful to understand differ-
ences between rubella and measles seroprevalence.
Materials and methods
We conducted a cross-sectional seroprevalence survey of anti-measles IgG and anti-rubella
IgG in children and adults in 2014 using representative samples from all 143 districts of Lao
PDR using a multistage random cluster sampling design.
Study population
The population covered by the 2011 SIA was aged 3–21 years at the time of the survey. Because
we aimed to evaluate the 2011 SIA, we included both the populations who would have defi-
nitely been covered and not covered by the 2011 SIA, namely those aged 5–21 years and 1–2
and>21 year olds respectively and compared the seroprevalence between them. Those aged
3–4 years were not included, because their immunization history and date of birth were diffi-
cult to determine as calendar and traditional ages are often confused in rural villages [8, 9]
(Table 1).
Sample size calculation
The required sample size (n) was calculated using the formula
n ¼ Z2  pð1   pÞDEFF= ðd2  RRÞ ¼
where n = sample size
Z = significance level for 95% confidence
p = expected prevalence
DEFF = design effect
d = precision
RR = response rate
In this, we used a 5% level of significance (Z = 1.96, the z-score needed for this in a two-
tailed test)), precision (d) of ±0.05 to ±0.06, and expected measles and rubella IgG-positive
rates (p) of 60% for children aged 1–2 years and 90% for children aged> 5 years and adults,
an expected design effect (DEFF) of 1.6, and a response rate (RR) of 99%. The required sample
size was calculated to be 416 samples for 1–2 year olds and 312 samples each for 5–14 year
olds, 15–19 year olds, and adults aged 40 years old or more. We previously found that adults
working in rice fields can be difficult to sample [8, 9], so we included 832 parents of children
aged 1–2 years. The survey required collection of 2,184 samples in total.
Survey design and sampling
A three-stage random cluster sampling design was adopted, as probability sampling is recom-
mended by the World Health Organization [10]. For the first stage, 26 of 143 districts were
randomly selected by applying probability proportionate to size (PPS) sampling based on the
latest population census of 2005 obtained from the Department of Statistics, Lao PDR. For the
second stage, 2 villages were randomly selected from each district by PPS sampling. For the
third stage, 42 participants were randomly selected using a paper-based lottery from a list of
households in each village satisfying the required sample size: 8 aged 1–2 years, 6 aged 5–14
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years, 6 aged 15–19 years, 16 parents of the 1–2 year olds, and 6 aged 40 years. We chose
these age groups for better field practicability because we used several registers as sources of
the resident lists (i.e., EPI register, poverty reduction programme log, and village head’s
register).
Data collection
The survey was conducted for 2 weeks from 27 January to 7 February, 2014. A survey team (2
members per team) was organized in each of the 26 selected districts and was expected to
investigate individuals sampled from 2 villages in the district. For smooth implementation of
the survey, team members were recruited from among district health officers in the district
because of their familiarity with the local cultural context and security information. The teams
Table 1. Reported coverage of routine immunization and supplementary immunization activities with measles containing vaccine by age at the survey in Lao PDR,
2014.
Age at the survey
(years)
Year of birth Routine MCV coverage (%) 2001 SIA using MCV 2007 SIA using MCV 2011 SIA using MRCV
1 2012 72
2 2011 69
3 2010 64 〇
4 2009 59 〇
5 2008 52 〇
6 2007 40 〇
7 2006 48 〇 〇
8 2005 41 〇 〇
9 2004 36 〇 〇
10 2003 42 〇 〇
11 2002 55 〇 〇
12 2001 50 〇 〇
13 2000 42 〇 〇 〇
14 1999 71 〇 〇 〇
15 1998 71 〇 〇 〇
16 1997 67 〇 〇 〇
17 1996 73 〇 〇
18 1995 68 〇 〇
19 1994 73 〇 〇
20 1993 46 〇 〇
21 1992 46 〇
22 1991 47
23 1990 32
24 1989 20
25 1988 23
26 1987 11
27 1986 10
28 1985 6
29 1984 6
30 1983 7
Reported coverage of SIAs in 2001, 2007, and 2011 are 86%, 96%, and 97%, respectively
SIA, supplementary immunization activities; MCV, measles containing vaccine; MRCV, measles and rubella containing vaccine
https://doi.org/10.1371/journal.pone.0194931.t001
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had two tasks for the investigation: (i) a brief face-to-face interview to obtain demographic
information and (ii) blood collection using a dried blood spot method by finger prick [11]. To
ensure compliance with survey procedures, team members were trained and supervised by
national government staff from the National Immunization Programme, National Centre for
Laboratory and Epidemiology, and the Ministry of Health as well as provincial health officers,
Lao PDR.
Anti-measles and anti-rubella IgG titres
A small amount of blood was spotted onto Whatman 903 Protein Saver filter paper (Whatman,
Maidstone, Kent, UK) by finger prick and air-dried for at least 60 min [11]. The filter papers
were sealed in plastic bags and transported to Japan within a few weeks. Blood samples were
extracted from dried blood spots on the filter paper [12], and IgG levels were measured using
commercially available enzyme-linked immunosorbent assay (ELISA) kits (Enzygnost Anti-
Measles Virus/IgG and Anti-Rubella Virus/IgG, Siemens Healthcare Diagnostics) according
to the manufacturer’s instructions at the Department of Virology 3, National Institute of Infec-
tious Diseases, Japan. Optical density values were converted to quantitative data, and the
results were considered positive at higher than 120 mIU/mL for measles and 10 IU/mL for
rubella [13, 14].
Estimation of the number of averted CRS cases, by mathematical modelling
Adapting methods used previously [7, 15–17], we first fitted four age-structured catalytic mod-
els to the observed weighted age-stratified serological data for those aged>21 years using max-
imum likelihood to estimate the average force of infection (the rate at which susceptibles are
infected) that children (< 15 years) and adults ( 15 years) experienced before the 2011 SIA
was introduced. The fitting just used data for those aged> 21 years in 2014 because they were
outside the age groups targeted by the 2011 SIA and so their seroprevalence would not have
been directly affected by vaccination. The force of infection was assumed to differ (models A
and B) or be identical (models C and D) for the ages<15 and15 years. The sensitivity of the
rubella serological (antibody) assay was either estimated (models A and C) or assumed to be
100% (models B and D). The models assumed that maternal immunity lasts for 6 months and
we explored the effect of assuming that the force of infection after the SIA was reduced by
either 0%, 25%, 50%, 75%, or 100%). The Supplementary Information provides further details
about the models and the equations. The force of infection used in subsequent calculations
(see below) was the one obtained from the model selected according to biological plausibility,
as described elsewhere [17].
The best-fitting value for the force of infection from the selected model was used to estimate
the CRS incidence per 100,000 live births in 2013 among women in 5 year age groups between
15 and 44 years and to estimate the CRS incidence if the SIA had not taken place in 2011. The
CRS incidence per 100,000 live births among women in age group A was given by the follow-
ing expression:
0:65 suðAÞð1   e
  16loð1  rÞ=52Þ  100000
where su(A) is the proportion of women in age group A that are susceptible, λ0 is the average
force of infection among those aged 15 years before the SIA was introduced, and r is the
average reduction in the force of infection after the SIA was introduced. For participants aged
15–21 years, su(A) was taken to equal the observed proportion of women in age group A who
were seronegative during the seroprevalence survey. For the other age groups, sU(A) was calcu-
lated using the appropriate expressions from the model (see Supplement). As in previous
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analyses [14], the risk of a child being born with CRS was assumed to be 65% when the mother
was infected during the first 16 weeks of pregnancy and zero thereafter. The CRS incidence
per 100,000 live births among women aged 15–44 years was calculated using the same
approach used elsewhere [14], as the mean CRS incidence per 100,000 live births for each
5-year maternal age group, weighted by the number of live births occurring for each maternal
age group in 2013. To obtain the number of infants with CRS born to women in each age
group, the CRS incidence per live birth among women in each age group for Lao PDR was
multiplied by the estimated number of live births among women in corresponding age groups
in 2013 for Lao PDR. These were then summed over the ages of 15–44 years to give the total
number of infants born with CRS in 2013. The number of live births among women in a given
age group was calculated by multiplying the age-specific fertility rates by the number of
females in each age group in 2013, both of which were extracted from the UN population data-
base, 2012 revision. The number of CRS cases in 2013 prevented by the 2011 SIA was calcu-
lated as the difference between the total number of CRS cases calculated using the CRS
incidence with the SIA in place and that calculated if the SIA had not been implemented.
Confidence intervals (CIs) for the force of infection and CRS incidence for each catalytic
model, and the number of CRS cases prevented by the SIA, were obtained by bootstrapping
using 1,000 bootstrap datasets generated with the approach employed by Shkedy et al. [18].
Stability testing of MR vaccines
To evaluate differences in heat sensitivity between two viruses (Edmonston-Zagreb measles
virus and Wistar RA27/3 rubella virus), a single lot of the MR vaccine (MR-VAC, Serum Insti-
tute of India) underwent a stability testing under both freeze-dried and reconstituted condi-
tions. Freeze-dried vaccines were incubated at 4˚C, 25˚C, or 35˚C for 1, 3, 7, 14, 21, or 28 days
and stored at –80˚C until used for titration. Reconstituted vaccines were incubated at 4˚C,
25˚C, or 35˚C for 1, 3, 6, 12, or 24 h or 2, 4, or 7 days and stored at –80˚C until used for
titration.
Infectivity titres of the measles vaccine component in the incubated MR vaccine was deter-
mined by the standard plaque assay on African green monkey kidney-derived Vero cells. Since
the rubella vaccine component also produces plaques on Vero cells, the rubella vaccine com-
ponent was neutralized by the anti-rubella virus antibody for 1 h at 4˚C before incubation of
Vero cells with the vaccine samples.
Infectivity titres of the rubella vaccine component in the incubated MR vaccine was deter-
mined by the standard plaque assay on the rabbit kidney-derived RK-13 cells [19]. The measles
vaccine component was not neutralized by the anti-measles virus antibody before titration,
because the measles vaccine component did not produce plaque on RK-13 cells and the plaque
numbers of rubella vaccine component were not affected by the neutralization of the measles
vaccine component (data not shown).
Data entry and statistical analysis
All of the collected data were double-entered and cleaned on a Microsoft Excel 2013 spread-
sheet. The statistical analysis was conducted using STATA version 13 and 14 (Stata Corp., Col-
lege Station, TX, USA). Calculations of the IgG prevalence among the participants considered
the multistage cluster sampling design and sampling weight of each participant to elicit repre-
sentative, unbiased results. Differences between the immunity of each age group were exam-
ined with Chi-square and Fisher’s exact tests. Statistical significance was set at p<0.05.
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Ethical considerations
The surveyors explained the detailed survey objectives and procedures to the local authorities
and selected participants verbally and in writing. Written informed consent was obtained
from all selected participants. When participants were aged < 15 years, they were explained
the survey objectives and procedures according to their level of understanding, and consent
was obtained from their parents or legal guardians. Participants’ names were not recorded.
The research proposal was approved by the National Center for Global Health and Medicine
(Japan, NCGM-G-001459-00), the ethics committee of the Ministry of Health (Lao PDR,
025-NECHR), and the National Institute of Infectious Diseases (Japan, NIID-494).
Results
The survey teams visited all 52 selected villages from the 26 districts and completed blood sam-
pling in 2,153 subjects. After 18 subjects were excluded from the study due to missing data,
this left data for 2,135 subjects (97.8% of the required sample size) for analysis. Mean age was
23.2 years, ranging from 1 to 81 years (95% CI: 22.5–23.9). Males accounted for 44.8% of all
selected subjects. The places of residence were the north for 26.9%, central region for 26.9%,
and south for 46.3%. Regarding ethnicity, 70.3% were Laolum and 29.7% were other minori-
ties. The average of the reported routine immunization coverage for measles containing vac-
cine was 71.0% [95% CI: 55.5–86.5]) in selected districts in 2012.
Estimated IgG prevalence of measles and rubella
Of the 2,135 selected subjects, 1,733 and 1,469 tested positive for measles and rubella IgG, respec-
tively. Estimated IgG prevalence was 83.9% for measles (95% CI: 83.8–84.0) and 75.4% for rubella
(95% CI: 75.3–75.5) after considering the sampling design and individual sampling weight.
As shown in Fig 1, the seroprevalence for measles IgG for 5–21 year olds, who would have
been vaccinated during the 2011 SIA was significantly higher than that of 1–2 year olds who
were born since the SIA (86.8% [95% CI: 83.0–90.6] vs. 48.6% [95% CI: 40.0–57.1]; p<0.001),
but lower than that of 22–39 year olds (86.8% [95% CI: 83.0–90.6] vs. 99.0% [95% CI: 98.3–
99.8]; p<0.001) who were not targeted by the SIA. In contrast (Fig 2), the seroprevalence for
rubella IgG for 5–21 year olds was significantly higher than that for people who were not vacci-
nated during the SIA (88.2% [95% CI: 84.5–91.8] vs. 50.7% [95% CI: 42.5–58.9] and 74.6%
[95% CI: 70.7–78.5] for 1–2 year olds and 22–39 year olds respectively, p<0.001 for both).
To examine whether immunity differed among the SIA-targeted age groups, we compared
measles and rubella IgG positivity between 5–14 and 15–21 year olds. The IgG-positive rate
was significantly different for measles—80.6% [95%CI: 74.8–86.3] and 92.7% [95%CI: 88.8–
96.6], respectively (p<0.001)—but not for rubella—90.2% [95%CI: 85.8–94.5] and 86.3% [95%
CI: (81.7–90.9], respectively.
Model-based estimates of CRS cases averted
Fig 3 compares the best-fitting predictions from the selected catalytic model (B) of the age-spe-
cific percentage seronegative against the observed data. For reference, S1 Table in the supple-
ment summarises the estimates obtained from each of the catalytic models. Table 1
summarizes the best-fitting estimates of the average force of infection before the 2011 SIA, the
CRS incidence in 2013 and the number of CRS cases in 2013 prevented by the 2011 SIA for dif-
ferent assumptions about the reduction in the force of infection after the SIA. For all assumed
values for the reduction in the force of infection after the 2011 SIA (Fig 3), the fit of the model
to the data was similar, as were the best-fitting values for the force of infection, although the
Population-based nationwide IgG serosurvey: Evaluation of SIA using measles and rubella combination vaccines
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latter had wide CIs (Table 2). Assuming that the force of infection decreased by 50% after the
SIA, the force of infection was estimated to be 80 (95% CI: 63–97) and 18 per 1000 (95% CI:
8–30) per 1000 susceptibles for those aged<15 years and 15 years respectively.
If the SIA had not been implemented in 2011, the CRS incidence was estimated to have
been approximately 93 per 100,000 live births (93 [95% CI: 37–172]) if the SIA was assumed to
have reduced the force of infection by 50% (Table 2). This corresponds to almost 160 infants
being born with CRS in 2013 (156 [95% CI: 61–288]).
The estimated CRS incidence after the SIA was sensitive to the assumed reduction in the
force of infection following the 2011 SIA (Table 2), ranging from 85 per 100,000 live births
[95%CI: 35–152] assuming no reduction in the force of infection to 37 per 100,000 live births
(95% CI: 15–66) assuming a 75% reduction. The corresponding estimated numbers of CRS
cases were 142[95%CI: 58–254] and 62 [95%CI: 26–111] babies born with CRS in 2013, respec-
tively (Table 2). The number of CRS cases prevented in 2013 ranged from 16 [95%CI: 0–50]
assuming no reduction in the force of infection to 92 [95%CI: 32–180] assuming a 75% reduc-
tion after the SIA had been introduced.
Stability test results
The infectious titre of the measles vaccine component was stable and remained over 104 PFU/
dose after incubation of the freeze-dried vaccine at 4˚C or 25˚C for 28 days (Fig 4). The
Fig 1. Measles IgG seroprevalence measured by ELISA in different age groups from representative populations of Lao PDR, 2014. An ELISA value of 120 mIU/
mL was considered positive. †Individuals 5–14 years old and 15–21 years old were among the targeted age groups of supplementary immunization activities conducted
in 2011 using the MR combination vaccine with coverage of 97%. Their IgG prevalence was estimated to be 86.8% (95% CI: 83.0–90.6).
https://doi.org/10.1371/journal.pone.0194931.g001
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infectious titre of the measles vaccine component decreased day by day at 35˚C incubation.
Although the titre was still higher than 103 PFU/dose, which is the minimum potency require-
ment of the measles vaccine, an approximately 85% reduction in the titre was observed after
incubation for 28 days. In contrast, incubation at all 3 different temperatures until 28 days did
not affect the infectious titre of the rubella vaccine component in the freeze-dried vaccines.
When vaccines were reconstituted and then incubated, the infectious titres of both vaccine
components were stable during incubation at 4˚C, whereas they reduced day by day during
incubation at 25˚C or 35˚C (Fig 5). In particular, by incubation at 35˚C, the infectious titres of
the measles and rubella vaccine components became less than 103 PFU/dose by 2 and 4 days,
respectively, and were less than 10 PFU/dose by 7 days. However, there were no clear differ-
ences between the stability kinetics of the measles and rubella vaccine components at all
temperatures.
Discussion
Our study has three major findings. First, the measles IgG prevalence estimated from ELISA
results for the 2011 SIA-targeted age groups was lower than the reported immunization cover-
age, and it was lower than the measles IgG prevalence estimated for young adults. Second, in
contrast, the estimated rubella IgG prevalence for the 2011 SIA-targeted age groups was higher
than that for young adults, who were unlikely to be vaccinated, and the estimated number of
Fig 2. Rubella IgG seroprevalence measured by ELISA in different age groups from representative populations in Lao PDR, 2014. An ELISA value of 10 IU/ml
was considered positive. †Individuals 5 to 14 years old and 15 to 21 years old were among the targeted age groups of supplementary immunization activities conducted
in 2011 using the MR combination vaccine with coverage of 97%. Their IgG prevalence was estimated to be 88.2% (95%CI: 84.5–91.8).
https://doi.org/10.1371/journal.pone.0194931.g002
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CRS cases averted by the 2011 SIA ranged from 16 to 92 cases in 2013, according to mathemat-
ical modelling. Third, the measles component in the same vaccine used during the 2011 SIA
was more heat sensitive than the rubella component under freeze-dried conditions.
Population immunity among the target age groups of the 2011 SIA
The anti-rubella IgG prevalence measured by IgG ELISA in the SIA target age groups (88.2%)
reached and even exceeded the immunization coverage threshold of 80% recommended by
Fig 3. Comparison between the predictions of age-specific percentage seronegative, obtained using the best-fitting catalytic model and the observed data. Bars
reflect 95% confidence intervals of the observed data. Lines reflect predictions from the best-fitting model.
https://doi.org/10.1371/journal.pone.0194931.g003
Table 2. Best-fitting values of the force of infection in Lao PDR before the 2011 SIA among participants aged < 15 and 15 years, obtained by the selected best-fit-
ting model (model B) for different assumptions about the reduction in the force of infection after the SIA, and CRS incidence per 100,000 live births among women
aged 15–44 years after weighting by the number of live births occurring among women in different maternal age groups.
Assumed reduction in force
of infection since 2011
Force of infection per
1000 (susceptibles)
before 2011
Loglike-lihood deviance
(degrees of freedom)
Weighted CRS incidence per
100,000 live births
Number of CRS cases in 2013
<15 years
old
15 years
old
Without
vaccination
With
vaccination
Without
vaccination
With
vaccination
Prevented
0% 79 (61,96) 18 (8,29) 61 (43) 95 (37,178) 85 (35,152) 158 (62,297) 142 (58,254) 16 (0,50)
25% 79 (62,97) 18 (8,29) 61 (43) 94 (37,175) 69 (28,122) 158 (62,293) 116 (47,204) 42 (11,92)
50% 80 (63,97) 18 (8,30) 61 (43) 93 (37,172) 53 (22,94) 156 (61,288) 89 (36,156) 67 (21,136)
75% 80 (64,97) 18 (8,29) 61 (43) 92 (36,170) 37 (15,66) 154 (61,285) 62 (26,111) 92 (32,180)
100% 81 (65,98) 18 (8,29) 61 (43) 92 (36,168) 21 (8,38) 153 (61,280) 35 (14,64) 118
(43,224)
Note. Confidence intervals were obtained by bootstrapping. Columns labelled “without vaccination” refer to estimated CRS incidence that might have occurred in 2013
if the SIA had not been implemented.
https://doi.org/10.1371/journal.pone.0194931.t002
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WHO to avoid the potential for an increase in the CRS burden following the introduction of
rubella-containing vaccination [6]. This high IgG seroprevalence would have been obtained by
the 2011 SIA, when rubella vaccine was introduced in the country for the first time, because
the seroprevalence in our study among those targeted by the SIA was higher than that of peo-
ple aged 22–39 years (88.2% and 74.6% respectively; p<0.001), who would have acquired
rubella immunity only by natural infection.
On the other hand, anti-measles IgG prevalence measured by ELISA in the SIA target age
groups did not reach the required threshold for effective measles control, which is generally
considered to be 93%-94% based on its basic reproduction number (R0) of 12–18 [2]. Young
adults aged 22 to 39 years likely acquired immunity against measles mainly by natural infec-
tion, as routine measles elimination effort did not start until 2000. Despite a high reported
Fig 4. Stability testing of freeze-dried measles and rubella combination vaccines. After incubation of freeze-dried vaccines at 4˚C (A), 25˚C (B), or 35˚C (C), titres of
measles and rubella viruses in the vaccines were measured by plaque assays. Filled squares and open circles indicate titres of measles and rubella viruses, respectively.
Means of three vials are shown. Error bars indicate standard deviations.
https://doi.org/10.1371/journal.pone.0194931.g004
Fig 5. Stability testing of reconstituted measles and rubella combination vaccines. After incubation of reconstituted vaccines at 4˚C (A), 25˚C (B), or 35˚C (C), titres
of measles and rubella viruses in the vaccines were measured by plaque assays. Filled squares and open circles indicate titres of measles and rubella viruses, respectively.
Means of three vials are shown. Error bars indicate standard deviations.
https://doi.org/10.1371/journal.pone.0194931.g005
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coverage for the 2007 and 2011 SIAs (96% and 97% respectively), the comparatively low sero-
prevalence seen in our study among those targeted (7–20 and 5–21 year olds in our survey)
suggest that they did not adequately raise population immunity. Moreover, the increase in the
measles IgG with age in the SIA target groups (80.6% in 5–14 years and 92.7% in 15–21 years,
p<0.001) implies that wild measles virus is still circulating in the community.
Model-based estimates of the number of CRS cases averted
We estimated that the number of CRS cases averted by the 2011 SIA ranged from 16 (95% CI:
0–50) to 92 (32–180) in 2013. The most important and serious consequence of rubella is CRS.
The risk of CRS depends on the gestational age at the time of maternal infection [20]. Rubella
vaccinations play a major role in preventing infants being born with CRS. Although many
countries have recently newly introduced rubella vaccine through SIA and routine immuniza-
tion, few have reported the impact of vaccination [21–23]. CRS may be prevented by (i) pro-
viding direct protection to women and/or schoolgirls (a selective vaccination strategy); (ii)
vaccinating children to provide indirect protection by reducing the transmission of rubella
virus (a childhood vaccination strategy); or (iii) a combination of the two [24]. The second
strategy was adopted through the 2011 SIA in Lao PDR. Although vaccinating women of child-
bearing age has the strongest impact as a rubella control strategy, our modelling estimates sug-
gest that vaccinating children alone has the potential to reduce the CRS incidence.
Stability testing
The results from the stability testing of the same vaccine that was used in the 2011 SIA indi-
cated that the measles component of the MR vaccine is more heat sensitive than the rubella
component under certain conditions. The cold chain temperature was not recorded before or
during the 2011 SIA and direct evidence of heat exposure destroying measles vaccine compo-
nents during the SIA does not exist. However, our field work during the survey and other
approaches revealed that inadequate handling of vaccine vials and incorrect preparation of
vaccines are not so rare (e.g., keeping vials out of the cold chain for several weeks or filling the
vaccine into the syringe the day before injection).
Various hypotheses have been advanced to explain measles outbreaks experienced by countries
that have performed SIAs with high coverage (i.e., 95%): inflow of unvaccinated immigrants,
underestimated denominators due to an unreliable census, improper injection practice, weak cold
chain, or a combination of these factors [25–28]. However, most of the time, these hypotheses
have never been proven or disproven because no systematic analysis is conducted. In our study in
Lao PDR, the reason why measles IgG prevalence increased by age (80.6% in 5–14 years old and
92.7% in 15–21 years old), but rubella did not among the target population of 2011 SIA can be
partly explained by differences in heat stability between the measles and rubella vaccine compo-
nents. The contribution of immunogenicity differences between measles and rubella vaccine com-
ponents is not clear. Taken together, this low prevalence might cause repeated measles outbreaks
in the country. Regular monitoring of immunization activities by vaccination coverage and sur-
veillance data is essential, and more accurate estimation of population immunity than just the
reported coverage (the seroprevalence survey) should be conducted when countries experience a
measles outbreak after SIA with high coverage. In such countries, samples should be obtained
from both SIA-targeted and -nontargeted ages from a representative population [29, 30].
Strengths of the study
This study is the first nationwide survey of the prevalence of anti-measles IgG antibody and
anti-rubella IgG antibody in a general population among SIA-targeted and -nontargeted ages.
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We applied multistage random cluster sampling to better represent the general population in
Lao PDR. The design effect of prevalence was calculated to be between 0.8 and 2.9, which was
acceptable as we set it at around 1.6 before the survey. Infants aged 1–2 years showed higher
design effects (2.85 for measles and 2.62 for rubella IgG prevalence), which may reflect local
epidemics and/or routine immunization coverage.
The background characteristics of our sampled population were similar to those of another
nationwide population-based study, the Lao PDR Social Indicator Survey (LSIS) conducted in
2010–2011. For example, the locations of current residences—north, central, and south—were
26.9%, 26.9%, and 46.3% in our survey and 32.2%, 49.1%, and 18.7% in the LSIS. The educa-
tion levels attained by mothers—none, primary school, secondary school or more—were
19.2%, 30.8%, and 50.0% in our survey and 16.4%, 32.2%, and 50.3% in the LSIS. The LSIS
applied the multistage stratified cluster sampling method and surveyed more than 13,000
women all over the country. A direct comparison of the populations sampled by the two differ-
ent surveys is difficult to perform as the primary objectives were different. Nonetheless, our
sampled population likely represents the general population in Lao PDR.
Limitations of the study
The effectiveness of immunization is difficult to evaluate in Lao PDR because the country has
more than 30 years’ experience of routine immunization with variable annual reported cover-
age and several SIAs using measles-containing vaccine. Currently, no reliable laboratory
method to differentiate natural exposure from vaccination is available for field epidemiological
studies using dried blood spots. Therefore, the results should be interpreted carefully.
Another limitation is that the immunization records were not obtained from the SIA target
age groups. Written records must provide additional valuable information on whether or not
each individual was actually administered the vaccine during the 2011 SIA. However, our pre-
vious study conducted in Lao PDR in 2011 and 2012 focusing on 5–9 year olds revealed that
less than one-fourth of participants had kept their records from the time of the survey [8, 9].
Thus, the collection of written immunization records from the SIA-targeted age groups is con-
sidered impractical.
There was a potential bias in our estimates of IgG prevalence among adults, given that they
were sampled from parents of 1–2 year olds. Parents may likely be exposed to measles and
rubella more often than adults of same age without 1–2 year old children. However, average
Lao families have six children, and child adoption is very common [31], thus prevalence in
parents may only be slightly overestimated.
Conclusions
We provide a quantitative analysis of the estimated IgG prevalence among the representative
population for SIA-targeted and SIA-nontargeted ages in Lao PDR. We conclude that the 2011
SIA were not sufficiently effective for measles because the estimated anti-measles IgG positivity
was lower than its herd immunity threshold. The IgG prevalence increased with age despite
the reported coverage of 97% in 2011, which implies that the wild measles virus is still circulat-
ing. However, the 2011 SIA appears to have been effective for rubella because of the high IgG
prevalence achieved and the mathematical modelling for the rubella immunity profile revealed
that a significant number of CRS cases may have been averted per year. The difference in the
effectiveness of the two vaccine antigens can be in part explained by the results of the stability
testing indicating that the measles component is more heat sensitive than the rubella compo-
nent. This finding suggests that vaccine management was not ideal. Further study is needed to
evaluate vaccine management, including vaccine temperature monitoring.
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Seroprevalence surveys of measles and rubella IgG provide valuable information on popula-
tion immunity and enable the effectiveness of past measles and rubella immunization activities
to be evaluated. Similar seroprevalence surveys should be conducted in countries with repeated
measles epidemics after SIAs which have achieved with high coverage (95%) to evaluate immu-
nization effectiveness.
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